GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmAust Ltd (ASX:PAA) » Definitions » Selling and Marketing Expense

PharmAust (ASX:PAA) Selling and Marketing Expense : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is PharmAust Selling and Marketing Expense?

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services. PharmAust's Selling and Marketing Expense for the six months ended in Dec. 2023 was A$0.00 Mil. Its Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

PharmAust Selling and Marketing Expense Historical Data

The historical data trend for PharmAust's Selling and Marketing Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmAust Selling and Marketing Expense Chart

PharmAust Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Selling and Marketing Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PharmAust Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Selling and Marketing Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PharmAust Selling and Marketing Expense Calculation

Selling and Marketing Expense is the aggregate total amount of expenses directly related to the marketing or selling of products or services.

Selling and Marketing Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmAust Selling and Marketing Expense Related Terms

Thank you for viewing the detailed overview of PharmAust's Selling and Marketing Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmAust (ASX:PAA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmAust Ltd (ASX:PAA) » Definitions » Selling and Marketing Expense
Comparable Companies
ASX:ACW ASX:OCC ASX:LTP ASX:ADO ASX:AGN ASX:PAR ASX:CYP ASX:BIT ASX:SPL ASX:EZZ OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ECQ:Germany ECQ:Germany
Address
1 Kyle Way, Suite 116, Claremont, Perth, WA, AUS, 6010
Website
https://www.pharmaust.com
PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.